Health Condition 1: null- Treatment resistant Depression and Schizophrenia being treated with brain stimulation therapies (electroconvulsive therapy or repetitive transcranial magnetic stimulation therapy)
Conditions
Interventions
None listed
Sponsors
All India Institute of Medical Sciences New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: Ability to read English and Hindi Willing to give informed consent Fulfilling criteria of depressive disorder as per Diagnostic and Statistical Manual 5 (DSM 5) in group 1 & 2 Fulfilling criteria of schizophrenia as per Diagnostic and Statistical Manual 5 (DSM 5) in group 3 & 4 Patients referred for MECT or rTMS (for all study patients, a clinical decision to pursue neuromodulation would have already been made. Clinical treatment will be performed independently of this study) Treatment resistance will be defined as the failure to receive benefit from at least one but no more than four adequate trials of antidepressant medication or two adequate trials of antipsychotic medications from different classes (Sackeim, 2001)
Exclusion criteria
Exclusion criteria: 1. Patients with chronic neurological or other physical illness 2. Suffering from any other psychiatric disorder other than depressive disorder and schizophrenia in their respective groups, as assessed by Mini International Neuropsychiatric Interview (MINI) screen 3. Persistent mood disorders (dysthymia) and other and unspecified depressions based on DSM 5 4. History of significant head trauma 5. Patients with alcohol or other substance abuse (except nicotine and caffeine) 6. Any history of seizure 7. Previous history of receiving any surgical procedures or electrical or magnetic stimulation on brain 8. Known or suspected pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in activation and connectivity seen on functional near infrared spectroscopy and electroencephalography during resting state as well as activation state (in response to emotional tasks) scans before and after brain stimulationTimepoint: First session and last session | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in BDNF levels, before and after brain stimulationTimepoint: First session and last session | — |
Countries
India
Contacts
Public ContactRohit Verma
All India Institute of Medical Sciences New Delhi
Outcome results
None listed